Learning Objectives: -Evaluate emerging efficacy and safety data regarding CTLA-4 inhibitor-containing regimens in mNSCLC -Plan strategies to use current and emerging biomarkers to select mNSCLC patients who are likely to benefit from therapy with dual PD-1 /CTLA-4 checkpoint blockade -Collaborate with members of other disciplines and professions to provide cutting-edge, cost-effective, equitable, and inclusive care for patients with mNSCLC
- Provider:Medical Learning Institute, Inc.
- Activity Link: https://app.cesessions.org
- Start Date: 2025-02-08 06:00:00
- End Date: 2025-02-08 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 10004.75 - Is Kind Support: False
- Activity Type: Live Course
- CME Finder Type: Conference
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Limited
Subscribe
Login
0 Comments
Oldest